Compare Quest Diagnostics Inc (DGX) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs NextEra Energy, Inc. — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while NextEra Energy, Inc. trades at $77.22 (market cap $160.75B). The key difference: NextEra Energy, Inc. is far larger — about 6.4× Quest Diagnostics Inc's market cap, and NextEra Energy, Inc. pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and NextEra Energy, Inc. for 83 Days on average.
| DGX | NEE | |
|---|---|---|
Market Cap | $25.06B | $160.75B |
Volume | 927,361 | 10,598,021 |
Sector | Health | Utilities |
52-Week High | $247.45 | $97.88 |
52-Week Low | $173.49 | $75.49 |
Typical Hold Time | 56 Days | 83 Days |
Enterprise Value | $30.82B | $268.08B |
Dividend Yield | 1.52% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
NextEra Energy (NEE) trades at $77.37, down 0.65% with a bearish technical signal. The stock shows strong fundamentals with 32.4% net income margin and 17.23% ROE, though recent earnings were mixed with a Q4 miss but Q1-Q2 beats. Analyst consensus remains bullish with 66.7% buy ratings and $96 price target. Recent news highlights growth opportunities including a $22.3 billion energy infrastructure partnership and 18 GW gas development prospects.
NEE presents a compelling long-term investment case with robust profitability and analyst support, though near-term technical weakness and rising debt levels warrant caution. The company's clean energy transition strategy and infrastructure projects provide growth catalysts, but interest rate sensitivity and execution risks on large projects represent key challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
